Insulin-like Growth Factor-1 (IGF-1) signalling in immunometabolism of TB and TB-Diabetes comorbidity
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Emerging Global Leader
Project Information in NIH RePORTER
Insulin-like Growth Factor-1 (IGF-1) signalling in immunometabolism of TB and TB-Diabetes comorbidity
Principal Institution
University of Cape Town
Principal Investigator(s) (PI)
Parihar, Suraj P.
Project Contact Information
Email:
suraj.parihar@uct.ac.za
Year(s) Awarded
2023-2028
Country
South Africa
Project Description
Diabetes is the second leading cause of deaths after tuberculosis (TB) in South Africa and increases the risk of developing TB. The functions of Insulin-like Growth Factor-1 (IGF-1) in metabolism, genetics, and immunity in TB and co-morbidity of TB/Type 2 diabetes mellitus (T2DM) has not been studies comprehensively. Using advanced training in immunometabolism and immunogenetics this project will define the associations of IGF-1/Insulinlike growth factor1 receptor (IGF1R) in patients and assess an IGF-1R inhibitor as adjunctive therapy (a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness) in vivo, to enhance our understanding of IGF-1 signaling in TB, T2DM and TB/T2DM comorbidity.
Related World Regions / Countries
Related Global Health Research Topics